Guggenheim Reiterates Buy on Assembly Biosciences, Maintains $43 Price Target

Assembly Biosciences, Inc.

Assembly Biosciences, Inc.

ASMB

0.00

Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ: ASMB) with a Buy and maintains $43 price target.